A-Scan Biometric Analyzer Model P20

Products	A-Scan Biometric Analyzer Model P20
Company	Paradigm Medical Industries, Inc.
Item	A-Scan Biometric Analyzer Model P20
Features	Maintenance-free, solid-tip, lighted probe. Automatic, semi-automatic, and manual mode operations. Corneal tone indicates probe contact. Foot pedal facilitates hands-free operation. Modular card interface allows for easy software updates. Lens data automatically inserted into each formula. Complete display of scan and intraocular dimensions, with select screening and editing. Stored axial length measurements are averaged automatically and inserted into IOL programs. Complete theoretic, regression, and adaptive IOL calculations. Patient and physician names recorded on the printout. Quiet, built-in printer. Automatic gates permit measurement with discrete tissue velocities.
Description	The most advanced IOL workstation. Accurate, efficient and easy to use. The Biometric Analyzer can be used with a variety of regressive, theoretical, and adaptive IOL calculation programs, according to the needs of the patient. Convenient design features improve your diagnostic technique, including a foot pedal for hands-free operation, audible tone to minimize corneal compression errors, on-line help screens that summarize procedures, and a built-in printer. Immersion biometry is an additional option available in the Paradigm P20. Another extra feature is the ability to adjust the instrument for silicone lens measurement.
Info	Paradigm Medical Industries, Inc. Customer Service: (801) 977-8970

TAG: Scan Biometric Analyzer Model

...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...

Medicine Products:

Glynase Glycine Glycated Albumin Glucotrol

(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...

(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...

(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...

(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...

Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2 Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2 Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2 Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3

[2] Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 [0] HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services [0] Chinese Work Sees Through Invisibility Quest [0] Domestic AIDS Epidemic Ignored at Republican National Convention

...ontessori schools have an advantage over other kid.... However, an early education researcher finds the...s study, thirty 5-year old kids and twenty nine 12...ner-city Montessori school in Milwaukee, Wis. were...

...alth (NIH) announced that they have finished the p...ics in Parkinson's disease//. The study is far fro...g point for future detailed studies. The study was...stitute of Aging (NIA) and National Institute of N...

...c Policy Center (GPPC) says that fertility clinics...ds' gender by using// a method called preimplantat...tended to allow embryos to be screened for deadly ... a 3-day-old embryo and screens for presence of ch...

...e that could detect hidden fractures once a person...kus and colleagues at Purdue University in Indiana...ound waves created by tiny cracks in damaged bones...on of Daily Mail. They then sound an alarm, warni...

Other Medicine News:Health News:Montessori Schools kids do better in Reading and Math 2 Health News:Parkinson's Disease And Genetics 2 Health News:Fertility Clinics Allowing Parents To Select Gender 2

Montessori Schools kids do better in Reading and Math Parkinson's Disease And Genetics Fertility Clinics Allowing Parents To Select Gender Prototype Bandages Developed that Could Detect Fractures

(Date:9/3/2008)... analysis showed that Multaq(R) (dronedarone) decr...rial fibrillation or atrial flutter already ...y, BRIDGEWATER, N.J., Sept. 3 /PRNewswire-FirstCa...ata from the ATHENA study were presented today at,...Society of Cardiology,congress 2008, in Munich, Ge...

(Date:9/3/2008)...mpany Focuses Operations, Updates Zingo Launch Pro...on Strategy Conference Call Today...t. 3 /- Anesiva,Inc. (Nasd...restructure,operations to focus on commercial and ...ransition to a specialty pharmaceutical pain manag...

(Date:9/3/2008)...B-509 to be Evaluated in Repeat-Dosing Study in Su...swire-FirstCall/ -- Sangamo,BioSciences, Inc. (Nas...Phase,2 clinical trial (SB-509-801) to evaluate it...e, degenerative motor-neuron disease for which the...ngamo,s drug, SB-509, is an injectable formulation...

(Date:9/2/2008)...W YORK, Sept. 3 /- Forest L...lmirall, S.A. today announced results from,two glo...el long-acting,inhaled anticholinergic for the tre...ary disease (COPD). In both the ACCLAIM/COPD I&II,...Safety In Moderate to,Severe COPD Patients) studie...

Breaking Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2 Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3 Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4 Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5 Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2 Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3 Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4 Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5 Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2 Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3 Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4 Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5 Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2 Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3 Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4 Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5 Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6 Indivumed Appoints Annette Kassen as Vice President Clinical Research 4500 1 Indivumed Appoints Annette Kassen as Vice President Clinical Research 4500 2 Rice Memorial Hospital Implements SinglePointe 28TM 29 Automated Patient Specific Management Solution From Omnicell 4498 1 Rice Memorial Hospital Implements SinglePointe 28TM 29 Automated Patient Specific Management Solution From Omnicell 4498 2 Rice Memorial Hospital Implements SinglePointe 28TM 29 Automated Patient Specific Management Solution From Omnicell 4498 3 Module map links embryonic stem cells and cancer stem cells 16381 1 Module map links embryonic stem cells and cancer stem cells 16381 2 26 23163 3B7 5m to transform patient care 16379 1 26 23163 3B7 5m to transform patient care 16379 2 26 23163 3B7 5m to transform patient care 16379 3

[0] Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation [0] Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company [0] Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)[0] Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)

...clinical data for potential combination,therapies ...after,ITMN-191 exposure, BARCELONA, Spain, April 1...announced today the presentation of findings from,...ease inhibitor,ITMN-191, alone or in combination w... the European Association for the Study of the,Liv...

...SS WIRE)--Apr 11, 2007 - New data,supporting the c...,the most advanced investigational oral protease i...HCV) infection, will be presented,at the 42nd Annu...dy of the Liver (EASL) in Barcelona this week. In ...een accepted for presentation,at the EASL conferen...

Other Medicine Technology:InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 2 InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 3 InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting 4 Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2 Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3 Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4 Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5 Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6

InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL)